Most Read Articles
Elaine Soliven, 5 days ago

Switching from efavirenz/emtricitabine/tenofovir disoproxil fumarate (EFV/FTC/TDF) to the new bictegravir/ emtricitabine/tenofovir alafenamide (BIC/FTC/TAF) regimen maintained high rates of virological suppression in adults who are living with HIV*, according to a study presented at AIDS 2020.

3 days ago
Among individuals with abdominal obesity, drinking beverages with artificial sweeteners (ASBs) or no sugar (USBs) instead of sugar-sweetened beverages (SSBs) helps lose body weight, a study has found. However, USBs have a more favourable effect on sweet taste preference compared with ASBs.
Stephen Padilla, 5 days ago
Pre-exposure prophylaxis (PrEP) containing either long-acting injectable cabotegravir (CAB) or tenofovir/emtricitabine (TDF/FTC) is safe and effective for transgender women (TGW) and cisgender men who have sex with men (MSM), but CAB results in a much lower HIV incidence compared to TDF/FTC, results of the HIV Prevention Trials Network (HPTN) 083 have shown.
Jairia Dela Cruz, 4 days ago
Monthly prophylaxis with the fixed-dose combination of naphthoquine-azithromycin (NQAZ) is well tolerated and confers significant protection against infection with Plasmodium parasites among individuals residing in malaria-endemic areas in Southeast Asia, as shown in the results of a phase III trial.

Baseline IOP affects selective laser trabeculoplasty success

23 Jun 2020
The future of eyesight restoration may come from a most unlikely corneal donor – pigs.

High baseline intraocular pressure (IOP) may influence treatment outcomes after selective laser trabeculoplasty (SLT), a recent study has found.

The study included 252 eyes from 198 adult patients (mean age, 69.6±11.2 years; 49.2 percent female) with open-angle glaucoma. SLT success was defined as a 20-percent decline in IOP reduction or a drop of at least one medication. The principal outcome was the identification of predictors of success.

Mean IOP at baseline was 17.8±4.4 mm Hg. Patients were taking an average of 2.0±1.3 glaucoma medications before surgery. Two months after surgery, 33.6 percent of the procedures were deemed to be successful. This climbed slightly to 38.5 percent by 6 months. IOP dropped to 16.7±4.3 and 15.2±4.9 mm Hg at the respective time points (p<0.001 for both).

Changes in the average number of medications changed to 1.6±1.3 at 2 months and 2.0±1.3 at 6 months, though none were significant (p=0.709 and p=0.578, respectively).

IOP was the only baseline factor that was significantly affective of SLT success. Those with baseline IOP >18 mm Hg saw a 17.3-percent (3.7±4.2 mm Hg) drop in IOP at month 2, as opposed to a 4.9-percent (–0.7±5.6 mm Hg) increase in those with baseline IOP 18 mm Hg.

This pattern persisted until 6 months. Participants with high baseline IOP saw a mean 2-month drop of 23.7 percent, as opposed to a 4.9-percent increase reported in those with low IOP at baseline (p<0.001). Baseline IOP was not related to changes in the mean number of medications.

Editor's Recommendations
Most Read Articles
Elaine Soliven, 5 days ago

Switching from efavirenz/emtricitabine/tenofovir disoproxil fumarate (EFV/FTC/TDF) to the new bictegravir/ emtricitabine/tenofovir alafenamide (BIC/FTC/TAF) regimen maintained high rates of virological suppression in adults who are living with HIV*, according to a study presented at AIDS 2020.

3 days ago
Among individuals with abdominal obesity, drinking beverages with artificial sweeteners (ASBs) or no sugar (USBs) instead of sugar-sweetened beverages (SSBs) helps lose body weight, a study has found. However, USBs have a more favourable effect on sweet taste preference compared with ASBs.
Stephen Padilla, 5 days ago
Pre-exposure prophylaxis (PrEP) containing either long-acting injectable cabotegravir (CAB) or tenofovir/emtricitabine (TDF/FTC) is safe and effective for transgender women (TGW) and cisgender men who have sex with men (MSM), but CAB results in a much lower HIV incidence compared to TDF/FTC, results of the HIV Prevention Trials Network (HPTN) 083 have shown.
Jairia Dela Cruz, 4 days ago
Monthly prophylaxis with the fixed-dose combination of naphthoquine-azithromycin (NQAZ) is well tolerated and confers significant protection against infection with Plasmodium parasites among individuals residing in malaria-endemic areas in Southeast Asia, as shown in the results of a phase III trial.